News From the Food and Drug Administration

17-03-2021 12:24

March 16, 2021

A cell-based gene therapy to treat adults with large B-cell lymphoma (LBCL) has received FDA approval. Lisocabtagene maraleucel, marketed as Breyanzi, is a chimeric antigen receptor T-cell (CAR-T) therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

Zurück

Einen Kommentar schreiben

Sie müssen sich anmelden, um Kommentare hinzuzufügen.

News

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

26-03-2021 09:58

Go to the ELCC/ESMO 2021 PRESS RELEASE

SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

25-03-2021 17:15

Go to the ELCC/ESMO 2021 PRESS RELEASE

ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

24-03-2021 09:47

ASCO and the oncology community are deeply saddened by the passing of José Baselga, MD, PhD, FASCO, on March 21, 2021, at age 61. Dr. Baselga died of Creutzfeldt-Jakob disease, a rare fatal neurodegenerative disorder, according to his family. READ MORE

Pembrolizumab + Lenvatinib Significantly Improved PFS & OS vs CT in Advanced Endometrial Cancer Following Prior Platinum-Based CT

22-03-2021 11:06

Read more

Rucaparib Significantly Improves PFS vs Chemotherapy in Later-line Ovarian Cancer with BRCA Mutation

22-03-2021 10:58

Read more

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

08-02-2021 10:02

Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial MORE INFO

News

News From the Food and Drug Administration

Einen Kommentar schreiben

News

New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

Pembrolizumab + Lenvatinib Significantly Improved PFS & OS vs CT in Advanced Endometrial Cancer Following Prior Platinum-Based CT

Rucaparib Significantly Improves PFS vs Chemotherapy in Later-line Ovarian Cancer with BRCA Mutation

News From the Food and Drug Administration

HOPOS – Erster nationaler Dachverband in der Schweiz/première organisation faîtière de Suisse

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

Newsletter